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ABSTRACT
Purpose: To evaluate the potential of the new prognos-
tic information gained by analyzing the coexpression of
epidermal growth factor receptor (EGFR) and cyclooxyge-
nase-2 (COX-2) in cervical cancer patients.
Experimental Design: Sixty-eight patients with Interna-
tional Federation of Gynecology and Obstetrics stage IIB
squamous cell carcinoma of the uterine cervix, who under-
went concurrent chemoradiotherapy between 1993 and
1996, were divided into the following four groups according
to their immunoreactivities for EGFR and COX-2 in paraf-
fin-embedded sections: (a) the EGFR-negative/COX-2-neg-
ative group (n 11); (b) the EGFR-negative/COX-2-positive
group (n 8); (c) the EGFR-positive/COX-2-negative group
(n  27); and (d) the EGFR-positive/COX-2-positive group
(n  22). The clinical features, patterns of treatment failure,
and survival data in the four groups were compared.
Results: Positive immunoreactivity for EGFR and
COX-2 was observed in 49 of 68 (72%) and 19 of 68 (28%),
respectively. However, no strong correlation was found be-
tween the levels of EGFR and COX-2 immunopositivity
(R2  0.05, P  0.07). Patients in the EGFR-positive/COX-
2-positive group had a higher likelihood of locoregional
recurrence than those in the other three groups (P  0.02).
Of the patients in the four groups, patients positive for both
oncoproteins were found to have the worst prognosis with an
overall 5-year disease-free survival rate of 55% compared
with 91% for the EGFR-negative/COX-2-negative patients,
88% for the EGFR-negative/COX-2-positive patients, and
69% for the EGFR-positive/COX-2-negative patients (P 
0.05, log-rank test). In addition, the synchronous coexpres-
sion of the EGFR and COX-2 oncoproteins was found to be
an independent prognostic factor by univariate and multi-
variate analyses (relative risk  4.0, P  0.03).
Conclusions: Given these observations, we conclude
that the coexpression of EGFR and COX-2 immunoreactiv-
ity may be used as a potent molecular risk factor for pre-
dicting the poor survival of patients with the International
Federation of Gynecology and Obstetrics stage IIB squa-
mous cell carcinoma of the uterine cervix.
INTRODUCTION
Because the molecular mechanisms of tumor aggressive-
ness are usually dependent on the proliferative stimuli induced
by various tumor promoters, numerous proto-oncogenes and
oncogenes regulating tumor cell growth, differentiation, and
motility have been investigated to identify molecular targets that
might be used as potential predictors of survival in the manage-
ment of cancer (1, 2). Of a number of biological markers,
epidermal growth factor receptor (EGFR) has received much
attention during the last decades. It is a trans-membrane glyco-
protein, which consists of the following three distinct domains:
(a) an external ligand-binding domain; (b) a short intramembra-
nous segment; and (c) a cytosolic domain with tyrosine kinase
activity (2–7). Ligand-induced dimerization and autophospho-
rylation of EGFR activates a signal transduction pathway by
activating intrinsic protein tyrosine kinase activity and the phos-
phorylation of several target proteins, which lead to increased
DNA replication and the stimulation of cellular differentiation
and proliferation (2). Increased EGFR expression has been
observed in many experimental cell lines and human tumors,
such as head and neck cancer (3), esophageal cancer (4), gastric
cancer (5), and cervical cancer (6–14). In the case of uterine
cervical cancer, the incidence of EGFR overexpression has been
variably reported to occur in 6–85% of cases according to the
detection techniques and methods used previously (7). Although
there have been a few contradictory results (14), the majority of
reports show that elevated levels of EGFR correlate with a more
aggressive biological behavior and are clinically relevant to
poor prognosis in cervical cancer patients (7–13).
On the other hand, cyclooxygenase (COX)-2, a key en-
zyme that catalyzes the conversion of arachidonic acid to pros-
taglandins and other eicosanoids, alters several cellular re-
sponses involved in cell cycle regulation, the inhibition of
apoptosis, extracellular matrix deposition, or pathological an-
giogenesis (15–21). It promotes carcinogenesis, tumor prolifer-
ation, and the growth and spread of cancer by mediating the
pathological processes that affect mitogenesis, cellular adhe-
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sion, and immune surveillance (15–18). Therefore, COX-2 over-
expression has also been considered an indicator of tumor
invasiveness and aggressiveness as well as a predictor of met-
astatic potential in various types of cancers (16, 17, 22), includ-
ing uterine cervical cancer (23, 24). A previous report showed
that elevated levels of COX-2 expression are closely linked to a
higher incidence of parametrial invasion and lymph node me-
tastases in early-stage uterine cervical cancer (23). Moreover,
increased COX-2 expression has been proposed recently as a
putative prognostic determinant of uterine cervical cancer (23–
25), consistent with EGFR overexpression.
Preclinical in vitro and in vivo studies have demonstrated
that the gene amplification and/or the protein expression of
COX-2 is rapidly induced in response to various tumor promot-
ers, growth factors, oncogenes, and carcinogens (15, 26–32). In
particular, activation of the EGFR signaling pathway enhances
the transcription of the rate-limiting COX-2 gene in several cell
types (15, 27–30). Although both EGFR and COX-2 enzyme are
known to play a vital role in oncogenic transformation, carci-
nogenesis, and tumor invasiveness (3–12, 15–17), little infor-
mation is available regarding the relationship between EGFR
and COX-2 in cultured cervical carcinoma cell lines or in human
cervical cancer. Moreover, the prognostic significance of the
coexpressions of EGFR and COX-2 has not been investigated
despite the fact that the separate overexpression of EGFR (7–13)
or COX-2 (23–25) is known as an independent prognostic
indicator in uterine cervical cancer patients. The aim of the
present study was to evaluate the potential of the new prognostic
information gained by analyzing the coexpression of EGFR and
COX-2 immunoreactivities in patients with squamous cell car-
cinoma of the uterine cervix.
MATERIALS AND METHODS
Patients and Treatment. Of the patient population iden-
tified through a search of the Tumor Registry Database main-
tained by the Department of Radiation Oncology at the Yonsei
Cancer Center, Yonsei University, College of Medicine (Seoul.
Korea), we chose 68 consecutive patients with stage IIB inva-
sive squamous cell carcinoma of the uterine cervix, who were
treated with concurrent chemoradiotherapy between 1992 and
1996. The clinical staging and histological classification used
for uterine cervical cancer were based on the International
Federation of Gynecology and Obstetrics classification and the
WHO (Geneva, Switzerland) classification. To make the study
population more homogeneous, those with small cell carcino-
mas or adenocarcinomas were excluded from the study. All the
International Federation of Gynecology and Obstetrics stage IIB
patients who were treated with neoadjuvant chemotherapy and
radiation or with radiotherapy alone were also excluded. Eligi-
ble criteria for the concurrent chemoradiotherapy protocol in-
cluded patients with high risk factors, such as tumor size4 cm,
lymphovascular permeation, or lymph node metastases on ab-
dominopelvic computed tomography or magnetic resonance im-
aging. All patients received a combination of external irradiation
and high-dose-rate intracavitary irradiation by a remote after-
loading system using Ir-192 sources (-Med II). External irra-
diation was delivered to the whole pelvis at a dose of 1.8
Gy/fraction, five times/week to a midline dose of 27–45 Gy,
before high-dose-rate intracavitary radiation involving six inser-
tions (twice per week) with a fractional dose of 5 Gy to a total
dose of 30 Gy at point A. After the high-dose-rate intracavitary
radiation, the patients received a second course of external
irradiation with central shielding up to a total external dose of
45–50.4 Gy. Three cycles of chemotherapy were given concom-
itantly in weeks 1, 4, and 7 of radiotherapy. The chemotherapy
regimens used were cisplatin and 5-fluorouracil. Cisplatin was
injected as a daily bolus dose of 100 mg/m2, and 5-fluorouracil
was administered as a 24-h continuous infusion at a dose of
1,000 mg/m2/day for 5 days. After completing the treatment,
patients were followed-up at 3-month intervals for at least 5
years or until death. The follow-up period for all patients ranged
from 8 to 108 months, with a median of 60 months in the entire
patient group and a median of 66 months in the surviving group.
Immunohistochemical Staining for EGFR and COX-2.
For immunohistochemical staining, the tissue array blocks were
made from 4 m-thick paraffin-embedded tissue blocks, which
were obtained from punch biopsy at the pretreatment period.
After an evaluation of the H&E-stained slides, donor blocks
were prepared. Using a 2-mm core needle, representative cancer
regions were chosen from the matching donor blocks and trans-
planted to the recipient blocks made with purified agar in 3.8 
2.2  0.5 cm frames. The recipient blocks were framed in the
mold, which was used to frame the conventional paraffin block.
Holes measuring 2 mm were made in the recipient blocks using
a core needle, and the agar core was discarded. Subsequently,
paraffin was added to the frame. Consecutive 4 m-thick sec-
tions were cut from the recipient blocks using an adhesive-
coated slide system (Instrumedics Inc., Hackensack, NJ), which
supported the cohesion of the 2-mm array elements on the glass.
Monoclonal mouse antihuman EGFR antibody and rabbit poly-
clonal antibody specific for human COX-2 were purchased from
DAKO (Carpinteria, CA) and Cayman (Ann Arbor, MI), respec-
tively. Immunostaining for EGFR and COX-2 oncoproteins was
performed using a modified avidin-biotin immunoperoxidase
technique, as described previously (29). Briefly, after deparaf-
finization with graded ethanol solutions, endogenous peroxidase
activity was blocked by immersion of slides in methanol with
0.3% hydrogen peroxide for 30 min. Antigen retrieval was then
performed using a 0.01 M sodium citrate-buffered saline (pH
6.0) in a microwave processor for 30 min at 95°C. The slides
were then rinsed in PBS for 5 min and blocked with a solution
of 10% normal rabbit serum in PBS for 10 min at room tem-
perature. Both antibodies to the EGFR and COX-2 oncoproteins
used for immunostaining the tumor specimens were incubated at
4°C overnight. Each antibody was preheated in a microwave
(650 W) for 10 min in a citrate buffer (pH 6.0). Nonspecific
mouse immunoglobulin G1 monoclonal antibodies (03001D;
PharMingen; 1 mg/ml) were used as a negative control. Tissues
were incubated with biotinylated horse antimouse secondary
antibodies at a 1:500 dilution (Vector Laboratories, Burlingame,
CA), followed by extensive washing and then treatment with
avidin-biotin peroxidase complex at 1:25 dilution. Diaminoben-
zene was used as the chromogen, and hematoxylin was used as
the nuclear counterstain.
Assessment of Immunostaining. To eliminate the pos-
sibility of individual bias, sections were examined microscopi-
cally by an experienced investigator unaware of the clinical
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information. The same pathologist reexamined all slides after a
1-month interval. Discrepancies in staining analysis were 5%.
Immunoreactivities were classified as a continuum from the
undetected level (0%) to diffuse and homogeneous staining
(100%).
Statistical Analysis. Patient’s characteristics and pat-
terns of treatment failure were compared by ANOVA and Fish-
er’s exact test. The correlation between EGFR and COX-2
expression was analyzed using the Pearson’s correlation. Al-
though different cutoff values of EGFR and COX-2 were tested
for the survival analyses, we decided to choose the best prog-
nostic cutoff point value as significant discriminators. If the
distributions of immunoreactivity exceeded 10%, the sample
was classified as positively stained. The probability of overall
actuarial survival and disease-free survival for each positive or
negative group was calculated by the Kaplan-Meier method, and
the difference between survivals was compared using the log-
rank test. Cox’s proportional hazards model was used to identify
prognostic factors influencing survival. Prognostic variables that
showed statistical significance by univariate analysis were then
included in the multivariate analysis to define variables of
independent significance. P  0.05 was considered statistically
significant.
RESULTS
Immunohistochemical Findings. Fig. 1 illustrates char-
acteristic membrane staining for EGFR. Immunoreactivity for
EGFR was most abundant along the cytoplasmic membranes of
tumor cells. However, the staining pattern was variable within
the tumor nest. Some cases showed intense staining-patterns
along an invading margin of the tumor nest (Fig. 1A–B),
whereas others revealed diffuse immunoreactivity within the
entire tumor nest (Fig. 1C–D). Although essentially no immu-
noreactivity for EGFR was found within normal cells, immu-
nostaining for anti-EGFR monoclonal antibody was occasion-
ally observed in the normal basal and parabasal squamous
epithelium. On the other hand, COX-2 immunopositivity was
entirely restricted to the cytoplasms of tumor cells (Fig. 2),
although perinuclear immunoreactivity was also observed in
some tumor cells. Focal or diffuse COX-2 staining was detected
in the front margin of the tumor nest (Fig. 2A–B) or within entire
infiltrating tumor nests (Fig. 2C–D). However, the cells of
Fig. 1 Epidermal growth factor receptor (EGFR) immunoreactivity was most abundant along the membranes of tumor cells although the staining
pattern was variable within the tumor nest. Some cases showed intense staining patterns along an invading margin of the tumor nest (A–B), whereas
others revealed diffuse immunoreactivity within the entire tumor nest (C–D).
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histologically normal areas adjacent to tumor did not show any
COX-2 immunoreactivity. The levels of EGFR and COX-2
expression represent continuous variables from 0% to 100%.
When positive immunoreactivity was defined as the extent of
the distribution of immunostaining that exceeded 10%, overall
positivity for EGFR and COX-2 was found in 49 of 68 (72%)
and 19 of 68 (28%), respectively. Of the 68 patients, 22 (32%)
showed the coexpression of EGFR and COX-2, whereas 11
(16%) expressed neither EGFR nor COX-2.
Clinical Features. All patients were divided into the
following four groups according to their EGFR and COX-2
expression status: (a) the EGFR-negative/COX-2-negative
group (n  11); (b) the EGFR-negative/COX-2-positive group
(n  8); (c) the EGFR-positive/COX-2-negative group (n 
27); and (d) the EGFR-positive/COX-2-positive group (n 22).
No significant differences in the ages or in the performance
status were found between the patients of the four groups. We
attempted to identify relationships among several clinical pa-
rameters, but no significant association was found in terms of
pathological subtype, tumor shape, tumor size, extent of
parametrial involvement, or pelvic lymph node status in the
four groups. The patient characteristics of groups are listed in
Table 1.
Relationship between Levels of EGFR and COX-2 Ex-
pressions. On comparing the frequency of COX-2 expression
in the EGFR-positive and EGFR-negative group, no relationship
was found between EGFR status and COX-2 expression. Of the
49 EGFR-positive tumors, 22 of 49 (45%) were positive for
COX-2, compared with 8 of 19 (42%) of the EGFR-negative
tumors (Fisher’s exact test, P  0.527). To investigate the
distribution of COX-2 level according to EGFR level, linear
regression analysis was performed; however, only a weak cor-
relation was observed (Pearson correlation, R2  0.05, P 
0.07; Fig. 3).
Patterns of Treatment Failure. At the time of this anal-
ysis, a total of 23 patients suffered tumor recurrence. The
majority of recurrences and/or metastatic diseases evolved
within 3 years of completing treatment. We classified the pat-
terns of treatment failure into the following three categories:
locoregional recurrence, extrapelvic lymph node metastasis, and
hematogenous metastasis. Patients in the EGFR-positive/COX-
2-positive group had a higher likelihood of locoregional recur-
Fig. 2 The immunoreactivities for cyclooxygenase (COX)-2 restricted to tumor cells within the cytoplasms. Focal or diffuse COX-2 staining was
detected in the front margin of the tumor nest (A–B) or within entire infiltrating tumor nests without preference (C–D). However, the cells of
histologically normal areas adjacent to tumor did not show any COX-2 immunoreactivity.
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rence (32%) than those in the other three groups (9%; P 0.02).
However, there were no significant differences in the rates of
extrapelvic lymph node failure including paraaortic and/or su-
praclavicular node metastases among the four groups. In partic-
ular, EGFR-positive/COX-2-positive patients did not show a
tendency to more frequently develop hematogenous metastases.
Table 2 shows the patterns of treatment failure for patients in the
four groups.
Survival and Prognostic Factors. On the basis of a
median follow-up of 60 months, the 5-year overall actuarial and
disease-free survival rates for the 68 patients who were treated
with radiotherapy and concurrent chemotherapy were 82% and
79%, respectively. When these patients were stratified into four
groups according to their EGFR and COX-2 expression statuses,
patients positive for both oncoproteins were found to have the
worst prognosis with an overall 5-year actuarial survival rate of
58% compared with 100% for the EGFR-negative/COX-2-neg-
ative patients, 100% for the EGFR-negative/COX-2-positive
patients, and 82% for the EGFR-positive/COX-2-negative pa-
tients (P 0.009, log-rank test). Most strikingly, approximately
two-thirds of the EGFR-positive/COX-2-positive patients died
of pelvic recurrence and/or extrapelvic metastases within 3
years. A similar trend was also observed in the disease-free
survivals of the patients in the four groups. Five-year disease-
Table 2 Patterns of treatment failure
Patterns of failure
No. of patients (%)
Statistical
significance
Negative or
either positivea
(n  46)
Both
positiveb
(n  22)
Locoregional recurrence 4 (9%) 7 (32%) 0.02
Extrapelvic LNc metastasis 3 (7%) 4 (18%) NS
Hematogenous metastasis 4 (9%) 1 (5%) NS
a Negative staining or positive immunoreactivities of either EGFR
or COX-2.
b Positive immunoreactivities of both EGFR and COX-2.
c LN, lymph node; NS, not significant; EGFR, epidermal growth
factor receptor; COX, cyclooxygenase.
Table 1 Patient characteristics
Characteristics
EGFRa () EGFR ()
Statistical
significanceCOX () COX () COX () COX ()
No. of patients 11 8 27 22
Age (yrs) NS
Median 59 50 55 51
Range 31–75 34–67 29–71 32–67
Karnofsky performance status NS
Median 80 80 80 80
Range 60–90 60–90 60–90 60–90
Pathology NS
LCK 3 2 10 6
LCNK 8 6 17 16
Tumor shape NS
Exophytic 1 2 7 9
Infiltrative 10 6 20 13
Tumor size (cm) NS
4 7 4 14 12
4 4 4 13 10
Extent of parametrial involvement NS
Unilateral/medialb 4 1 14 8
Bilateral/lateralc 7 7 13 14
Pelvic LN involvement 1 3 1 7 NS
CT cycle (median) 3 3 3 3 NS
RT dose (Gy) NS
Median 84 84 84 84
Range 75–86.8 75–84 75–93 75–102
a EGFR, epidermal growth factor receptor; COX, cyclooxygenase; LCK, large cell keratinizing; LCNK, large cell nonkeratinizing; LN, lymph
node; CT, chemotherapy; RT, radiotherapy; NS, not significant.
b Unilateral and medial-half extension.
c Bilateral or lateral-half extension.
Fig. 3 Linear regression analysis between levels of epidermal growth
factor receptor (EGFR) and cyclooxygenase (COX)-2 expressions. No
strong correlation was observed between EGFR level and COX-2 im-
munopositivity (Pearson correlation, R2  0.05, P  0.07).
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free survival was 91% for the EGFR-negative/COX-2-negative
patients, 88% for the EGFR-negative/COX-2-positive patients,
69% for the EGFR-positive/COX-2-negative patients, and 55%
for the EGFR-positive/COX-2-positive patients (P  0.05, log-
rank test). The overall 5-year actuarial and disease-free survival
curves for each group are shown in Fig. 4. As expected, lymph
node metastasis was an important prognostic factor influencing
5-year disease-free survival rate by univariate analysis. Apart
from the coexpression of EGFR and COX-2, the separate ex-
pressions of EGFR or COX-2 were also statistically significant
prognostic factors. However, only the coexpression of EGFR
and COX-2 was an independent predictive factor for poor over-
all disease-free survival by multivariate analysis (95% confi-
dence interval; 2.7–5.3, P  0.03; Table 3).
DISCUSSION
Although several studies have found that the expressions of
EGFR (7–13) or COX-2 (23–25) are unfavorable prognostic
markers in cervical cancer patients, synchronous coexpression
of these oncoproteins in terms of their clinical and prognostic
significance has not been addressed. The present study demon-
strates that patients coexpressing both oncoproteins have a
higher likelihood of locoregional recurrence than those express-
ing EGFR or COX-2 alone. Simultaneously, it was found that
compared with separate expression of either oncoprotein alone,
the synchronous coexpression of EGFR and COX-2 immuno-
reactivities was a more significant and independent prognostic
factor for predicting poorer survival in the International Feder-
ation of Gynecology and Obstetrics stage IIB cervical cancer
patients treated with concurrent chemoradiotherapy. These ob-
servations suggest that cervical cancers with synchronous coex-
pression of EGFR and COX-2 are responsible for either the
more malignant phenotype with an aggressive biological behav-
ior or the further increased resistance to standard chemotherapy
and radiotherapy.
It is well recognized that the activity of the COX-2 pro-
moter and the induction of COX-2 enzyme are stimulated by
receptor-mediated signals triggered by epidermal growth factor,
transforming growth factor 	, and ligands of EGFR (15, 30).
Although the cis-acting elements in the COX-2 promoter, the
transcription factors modulating COX-2 expression, and the
signaling pathways from activated EGFR to the COX gene are
specific and independent for the pathological processes and
tissue types involved (15), EGFR/Ras and phosphatidylinositol
3-kinase signaling seem likely to be principally responsible for
the EGFR-mediated induction of COX-2 in squamous cell lines,
which is associated with the activation of mitogen-activated
protein kinase and increased activator protein 1 activity (27, 29,
31). In practice, COX-2 promoter activity is stimulated by the
c-Jun, a component of the activator protein 1 transcription factor
complex (29, 33–35). Conversely, the blockade of the EGFR
pathway markedly reduces baseline COX-2 activities. Anti-
EGFR antibodies or EGFR-selective kinase inhibitors almost
totally block the induction of COX-2 enzyme in various cell
lines (27, 29, 30, 36), and the pharmacological inhibition of
phosphatidylinositol 3-kinase, mitogen-activated protein kinase,
and p38 mitogen-activated protein kinase markedly suppressed
the induction of COX-2 enzyme mediated by epidermal growth
factor in cultured human uterine cervical cancer cells (29).
Additional data indicate that a dominant-negative mutant for
extracellular signal-regulated kinase 1, c-Jun, and p38 mitogen-
activated protein kinase blocks the activation of COX-2 pro-
moter activity, which is mediated by epidermal growth factor
(29, 33, 34, 37). Given these observations, it is apparent that the
activation of EGFR may be a major pathway involved in the
up-regulation of COX-2 enzyme. Nonetheless, our data failed to
demonstrate a strong correlation between the expressions of
EGFR and COX-2; for example, patients in the EGFR-positive
group showed no greater tendency toward higher COX-2 ex-
pression than those in the EGFR-negative group, nor were the
Fig. 4 Comparison of overall actuarial survival rates (A) and disease-
free survival rates (B) according to epidermal growth factor receptor
(EGFR) and cyclooxygenase (COX)-2 overexpression (Kaplan-Meier
method). Patients showing positive immunoreactivity for both EGFR
and COX-2 (solid line) showed the worst prognosis.
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levels of EGFR and COX-2 immunoreactivity closely related.
This lack of positive correlation between the expressions of
EGFR and COX-2 can be partly explained by the fact that the
COX-2 enzyme in cancer cells is mediated by various stimuli,
such as phorbol esters, cyclic AMP, hormone, or cytokines, as
well as various growth factors. Matsuura et al. (30) observed
that the activation of EGFR and the production of transforming
growth factor 	 highly up-regulated COX-2 mRNA mediated by
IFN- in both normal keratinocytes and squamous cell lines,
although treatment with either IFN- or transforming growth
factor 	 did not induce COX-2 expression in some squamous
cell lines, indicating that high levels of EGFR do not necessarily
result in COX-2 overexpression.
Although COX-2 transcription may be regulated by the
EGFR signaling pathway as well as a number of shared or
convergent EGFR-independent pathways, it is clear that auto-
crine/paracrine signalings of EGFR or COX-2 amplification
seem likely to be closely linked to a variety of biological
processes associated with cancer aggressiveness and metastatic
potential (2–6). Activation of EGFR signaling in human carci-
noma cell lines is responsible for an invasive phenotype
achieved by increasing cell motility and by producing matrix
metalloproteinase-9, which degrades the basement membrane
during tumor invasion and metastasis (2). Simultaneously,
COX-2 is also associated with the prevention of apoptosis (17,
18) and the induction of tumor angiogenesis (19–20), which are
all crucial to the promotion of tumor progression and dissemi-
nation. However, it remains to be answered how the coordinated
regulation of EGFR and COX-2 contributes to further promote
their biological activities by influencing important steps of
tumor invasion and metastasis. According to a few studies,
COX-2 enzyme enhances mitogenesis and cell proliferation
processes that are stimulated by various growth factors (26, 30,
38–40). Conversely, the inhibition of COX-2 expression or
activity not only inhibits epidermal growth factor-dependent
mitogenesis in mouse keratinocytes (38), but it also attenuates
transforming growth factor 	-dependent mitogenic effects in rat
intestinal epithelial cells (26). By promoting adhesion to the
extracellular matrix and transcription of the angiogenetic fac-
tors, COX-2 enzyme is likely to further enhance the mitogenesis
and cancer invasiveness, mediated by EGFR activation (2, 26).
These findings may, in part, explain why the synchronous
coexpression of EGFR and COX-2 represents a more aggressive
phenotype in uterine cervical cancer.
Perhaps the most notable result of the current study is that
the synchronous coexpression of EGFR and COX-2 was iden-
tified as a new and independent prognostic marker for cervical
cancer. Moreover, such patients showed poorer survival than
others, irrespective of well-established clinicopathological prog-
nostic parameters. Most strikingly, approximately two-thirds of
such patients died of pelvic recurrence and/or extrapelvic me-
tastases within 3 years. It seems likely that the aberrant expres-
sions of EGFR and COX-2 in cancer cells, at either the quan-
titative or qualitative level, may be associated with the increased
proliferation of tumor cells during and after radiotherapy, as
well as increased tumor cell resistance to chemotherapy and
radiotherapy. Therefore, controlling the EGFR and COX-2 ac-
tivities of cancer cells may reduce the tumor cell repopulation
and/or modulate chemosensitivity and intrinsic radiosensitivity
(1, 2, 41). Numerous studies have demonstrated that either
Table 3 Analysis of the prognostic factors influencing 5-year disease-free survival
Prognostic variables
No. of
patients
Univariate analysis
Statistical
significance
Multivariate
analysis
Statistical
significance% 95% CIa RR 95% CI
Age (yrs)
55 35 63 47–79 NS 2.4 1.3–3.5 NS
55 33 81 67–95
Tumor size (cm)
4 37 67 49–85 NS 0.7 0–1.7 NS
4 31 74 58–90
Pelvic LN involvement
No 56 84 74–94 0.03 2.0 0.7–2.3 NS
Yes 12 58 30–86
Parametrial extension
Unilateral/Medialb 30 80 64–96 NS 1.8 0.8–2.8 NS
Bilateral/Lateralc 38 65 49–81
EGFR expression
Negative 19 89 75–100 0.01
Positive 49 63 49–77
COX-2 expression
Negative 38 76 61–91 0.04
Positive 30 63 45–81
EGFR & COX-2 co-expression
Negative or either positive 46 78 65–91 0.001 4.0 2.7–5.3 0.03
Both positive 22 55 34–76
a CI, confidence interval; LN, lymph node; NS, not significant; RR, relative risk; EGFR, epidermal growth factor receptor; COX, cyclooxyge-
nase.
b Unilateral and medial-half extension.
c Bilateral or lateral-half extension.
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tyrosine kinase inhibitors or nonsteroidal anti-inflammatory
drugs suppress tumor angiogenesis and regress tumor growth in
vivo by reduced VEGF production (1, 2, 41–44). When com-
bined with cytotoxic drugs and/or radiotherapy, EGFR antibod-
ies or small-molecule EGFR tyrosine kinase inhibitors (1, 2), as
well as selective COX-2 inhibitiors (41–44) enhance the effi-
cacy of anticancer activity in several murine carcinomas, in
ways that may be of clinical relevance. Furthermore, we expect
that a combination of both EGFR inhibitor and COX-2 inhibitor
may be more effective than either agent alone in the manage-
ment of cervical cancer patients with coexpression of both
oncogenes (41). Clearly, however, this type of strategy will need
to be tested in appropriate preclinical models before studies in
human beings can be considered.
In summary, our data suggest that the synchronous coex-
pression of EGFR and COX-2 immunoreactivity is an independ-
ent prognostic factor in uterine cervical cancers. Moreover,
because the immunohistochemical detection of EGFR and
COX-2 coexpression usefully identifies a subset of patients with
an unfavorable prognosis, the targeting of EGFR signaling path-
ways, in combination with the selective inhibition of COX-2, is
believed to offer a novel approach for the management of such
patients. However, the molecular bases of these relationships
remain to be further elucidated, which is why their coexpression
reflects an aggressive phenotype with increased resistance to
standard chemotherapy and radiotherapy.
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